Coegin Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-23.78	-27.98	-35.24	-27.15	-46.24
Depreciation & Amortization	3.02	3.02	2.72	0.01	0.02
Other Operating Activities	0.01	0.01	-	-	37.14
Change in Accounts Receivable	-0.5	2.49	1.52	-2.18	2.36
Change in Other Net Operating Assets	-2.39	0.44	-7.24	7.83	-1.06
Operating Cash Flow	-23.64	-22.02	-38.23	-21.49	-7.78
Cash Acquisitions	-0.05	-	12.01	-	-
Investing Cash Flow	-0.05	-	12.01	-	-
Long-Term Debt Issued	-	4	4	-	-
Long-Term Debt Repaid	-3.5	-4	-	-	-
Net Debt Issued (Repaid)	-3.5	-	4	-	-
Issuance of Common Stock	45.03	26.83	-	31.73	16.93
Other Financing Activities	-3.66	-3.08	-	-2.39	6.93
Financing Cash Flow	37.87	23.75	4	29.35	23.86
Foreign Exchange Rate Adjustments	-0.05	-	0.38	1.15	-1.2
Net Cash Flow	14.13	1.73	-21.84	9.01	14.88
Levered Free Cash Flow	-19.34	-11.46	-19.61	-11.33	-
Unlevered Free Cash Flow	-18.96	-11.43	-19.47	-11.33	-
Change in Net Working Capital	7.4	-2.94	0.51	-5.65	-

Updated Jan 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.